checkAd

     153  0 Kommentare Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering - Seite 4

    About Collegium Pharmaceutical, Inc.

    Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding: whether Collegium will issue the notes; the expected amount and intended use of the net proceeds from the offering; Collegium’s expectations regarding the effects of the 2026 notes repurchases; and whether the 2026 notes repurchases will close. Collegium may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements represent Collegium’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are risks related to market conditions, the satisfaction of the closing conditions related to the offering and risks relating to the transactions, Collegium and its business, including those described under the heading “Risk Factors” in Collegium’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and other filings with the SEC, and in the preliminary offering memorandum related to the offering. Collegium may not consummate the offering or the 2026 notes repurchases described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds from the offering as described above. Any forward-looking statements included in this press release speak only as of the date of this press release. Collegium does not undertake any obligation to update the statements included in this press release for subsequent developments, whether as a result of new information, future events or otherwise, except as may be required by law.

    Seite 4 von 5



    globenewswire
    0 Follower
    Autor folgen

    Weitere Artikel des Autors

    Verfasst von globenewswire
    Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering - Seite 4 STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) - Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a …